Cargando…

Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma

PARP inhibitors can be used to treat solid tumors that often have mutations in important homologous recombination (HR) genes, such as BRCA1/2. While other kinds of tumors could also experience HR deficiencies, including those associated with lung cancer, there is little information on the frequency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Xueqian, Qi, Kang, Liu, Xiangzheng, Liu, Qinghao, Zhang, Xining, Wang, Dongliang, Huang, Weiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562462/ https://www.ncbi.nlm.nih.gov/pubmed/36249053 http://dx.doi.org/10.3389/fonc.2022.854999

Ejemplares similares

Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer
por: Liu, Xiangzheng, et al.
Publicado: (2021)

Methylation‐ and homologous recombination deficiency‐related mutant genes predict the prognosis of lung adenocarcinoma
por: Nie, Guang‐Jie, et al.
Publicado: (2022)

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
por: Golesworthy, Bryn, et al.
Publicado: (2022)

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
por: Liu, Hangqi, et al.
Publicado: (2022)

An Immune-Related Signature Predicts Survival in Patients With Lung Adenocarcinoma
por: Zhang, Minghui, et al.
Publicado: (2019)

RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma
por: Liu, Bing, et al.
Publicado: (2021)

A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
por: Zhang, Xun, et al.
Publicado: (2023)

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
por: Chiang, Ying-Cheng, et al.
Publicado: (2021)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
por: Cheng, Yang, et al.
Publicado: (2021)

Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma
por: Yin, Zhengrong, et al.
Publicado: (2022)

Left versus right approach for middle and lower esophageal squamous cell carcinoma: A propensity score-matched study
por: Zhang, Xining, et al.
Publicado: (2022)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

Cuproptosis-related lncRNA signatures: Predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma
por: Zhang, Pengpeng, et al.
Publicado: (2023)

High-Frequency Homologous Recombination Occurred Preferentially in Populus
por: Geng, Xining, et al.
Publicado: (2021)

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
por: Yi, Lilan, et al.
Publicado: (2022)

A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma
por: Zhu, Liping, et al.
Publicado: (2021)

Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis
por: Huang, Hua, et al.
Publicado: (2022)

Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
por: Zhou, Xiang, et al.
Publicado: (2023)

Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions
por: Zhang, Meng, et al.
Publicado: (2021)

Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol
por: Liao, Hao, et al.
Publicado: (2022)

Is homologous recombination really an error-free process?
por: Guirouilh-Barbat, Josée, et al.
Publicado: (2014)

Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses
por: Chen, Donglai, et al.
Publicado: (2021)

Development of a Prognostic Alternative Splicing Signature Associated With Tumor Microenvironment Immune Profiles in Lung Adenocarcinoma
por: Bao, Guangyao, et al.
Publicado: (2022)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2023)

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients
por: Liu, Yixiao, et al.
Publicado: (2023)

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma
por: Chen, Fangyu, et al.
Publicado: (2021)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
por: Wu, Gujie, et al.
Publicado: (2023)

A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level
por: Zhuang, Shuping, et al.
Publicado: (2021)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Prognostic Implication of Energy Metabolism-Related Gene Signatures in Lung Adenocarcinoma
por: Mu, Teng, et al.
Publicado: (2022)

A prognostic signature model for unveiling tumor progression in lung adenocarcinoma
por: Li, Zijian, et al.
Publicado: (2022)

Construction of a Novel Ferroptosis-Related Gene Signature for Predicting Survival of Patients With Lung Adenocarcinoma
por: Song, Xiaojie, et al.
Publicado: (2022)

A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma
por: Song, Congkuan, et al.
Publicado: (2020)

Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies
por: Xue, Liang, et al.
Publicado: (2020)

Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors
por: Gu, Peng, et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report
por: Zhuang, Junlong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ph97guo0kt3f5f2rab9hpo8l94